CHMP konkluderede derfor, at fordelene ved Valdoxan er større end risiciene ved behandling af voksne med alvorlige episoder af depression.
Therefore, the CHMP decided that Valdoxan’ s benefits are greater than its risks for the treatment of major depressive episodes in adults.